Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors

BMC Cancer

Pan-Chyr Yang¹  Chong-Jen Yu¹  Chih-Hsin Yang²  Chao-Chi Ho¹  Jin-Yuan Shih¹  Kuan-Yu Chen¹  Chia-Lin Hsu¹ 

[1]Division of Pulmonary Medicine, Department of Internal Medicine, National Taiwan University Hospital, and College of Medicine, Taipei, Taiwan

[2]Department of Oncology, National Taiwan University Hospital, and College of Medicine, Taipei, Taiwan

关键词: Young patients;    Prognosis;    Lung cancer;   

Others  :  1080366
DOI  :  10.1186/1471-2407-12-241

 received in 2012-01-17, accepted in 2012-06-13,  发布年份 2012

【 摘 要 】

Background

Lung cancer in young patients (less or equal to 45 years) is uncommon and has clinical characteristics different from that in older patients. We investigated the outcomes and prognostic factors of young patients with advanced non-small cell lung cancer (NSCLC).

Methods

From January 2000 to December 2009, we enrolled patients aged ≤45 years and diagnosed with stage IIIB or IV NSCLC. Their clinical data, including age, gender, performance status, histologic types, disease stages, laboratory data at diagnosis, treatment modalities, and survival were reviewed and analyzed. A Cox proportional hazard model was used to calculate the hazard ratio (HR) and its 95% confidence interval (CI).

Results

A total of 144 patients with advanced NSCLC were included. Female patients were more prevalent (n = 74, 51.4%). Adenocarcinoma was the most common histologic type (n = 119, 82.6%) in both genders (male, n = 54, 77.1%; female, n = 65, 87.8%). Epidermal growth factor receptor (EGFR) sequences were determined using tumor specimens from 58 patients, and 29 showed an EGFR mutation. No significant difference in median survival was found between patient groups with and without the EGFR mutation (798 vs. 708 days, p = 0.65). In multivariate analysis, male gender (HR, 1.70; 95% CI: 1.08-2.68), body mass index (BMI) less than 25 kg/m² (HR, 2.72; 95% CI: 1.39-5.30), stage IV disease (HR, 2.62; 95% CI: 1.50-4.57), and anemia (HR, 2.08; 95% CI: 1.15-3.77) were associated with a short survival time.

Conclusions

Low BMI, stage IV disease, anemia at diagnosis, and male gender were the negative prognostic factors for young patients with advanced NSCLC.

【 授权许可】

   
2012 Hsu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300.
• [2]Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, et al.: Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011, 377(9760):127-138.
• [3]Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, Santaquilani M: Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study. Lancet Oncol 2007, 8(9):773-783.
• [4]Zhang J, Chen SF, Zhen Y, Xiang J, Wu C, Bao P, Luketich J, Hu H, Zhou X, Yao S, et al.: Multicenter analysis of lung cancer patients younger than 45 years in Shanghai. Cancer 2010, 116(15):3656-3662.
• [5]Subramanian J, Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Piccirillo J, Govindan R: Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis. J Thorac Oncol 2010, 5(1):23-28.
• [6]Kuo CW, Chen YM, Chao JY, Tsai CM, Perng RP: Non-small cell lung cancer in very young and very old patients. Chest 2000, 117(2):354-357.
• [7]Liam CK, Lim KH, Wong CM: Lung cancer in patients younger than 40 years in a multiracial Asian country. Respirology 2000, 5(4):355-361.
• [8]Ak G, Metintas M, Metintas S, Yildirim H, Erginel S, Alatas F: Lung cancer in individuals less than 50 years of age. Lung 2007, 185(5):279-286.
• [9]Strand TE, Malayeri C, Eskonsipo PK, Grimsrud TK, Norstein J, Grotmol T: Adolescent smoking and trends in lung cancer incidence among young adults in Norway 1954–1998. Cancer Causes Control 2004, 15(1):27-33.
• [10]Marugame T, Yoshimi I, Kamo K, Imamura Y, Kaneko S, Mizuno S, Sobue T: Trends in lung cancer mortality among young adults in Japan. Jpn J Clin Oncol 2005, 35(4):177-180.
• [11]Chen KY, Chang CH, Yu CJ, Kuo SH, Yang PC: Distribution according to histologic type and outcome by gender and age group in Taiwanese patients with lung carcinoma. Cancer 2005, 103(12):2566-2574.
• [12]Capewell S, Wathen CG, Sankaran R, Sudlow MF: Lung cancer in young patients. Respir Med 1992, 86(6):499-502.
• [13]Skarin AT, Herbst RS, Leong TL, Bailey A, Sugarbaker D: Lung cancer in patients under age 40. Lung Cancer 2001, 32(3):255-264.
• [14]Bourke W, Milstein D, Giura R, Donghi M, Luisetti M, Rubin AH, Smith LJ: Lung cancer in young adults. Chest 1992, 102(6):1723-1729.
• [15]Zou B, Xu Y, Li T, Li W, Tang B, Zhou L, Li L, Liu Y, Zhu J, Huang M, et al.: A multicenter retrospective analysis of survival outcome following postoperative chemoradiotherapy in non-small-cell lung cancer patients with N2 nodal disease. Int J Radiat Oncol Biol Phys 2010, 77(2):321-328.
• [16]Radzikowska E, Roszkowski K, Glaz P: Lung cancer in patients under 50 years old. Lung Cancer 2001, 33(2–3):203-211.
• [17]Ramalingam S, Pawlish K, Gadgeel S, Demers R, Kalemkerian GP: Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database. J Clin Oncol 1998, 16(2):651-657.
• [18]Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 1997, 111(6):1710-1717.
• [19]Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304(5676):1497-1500.
• [20]Dai XD, Lin CY, Sun XW, Shi YB, Lin YJ: The etiology of lung cancer in nonsmoking females in Harbin, China. Lung Cancer 1996, 14(Suppl 1):S85-S91.
• [21]Munstedt K, Wagner M, Kullmer U, Hackethal A, Franke FE: Influence of body mass index on prognosis in gynecological malignancies. Cancer Causes Control 2008, 19(9):909-916.
• [22]Mauland KK, Trovik J, Wik E, Raeder MB, Njolstad TS, Stefansson IM, Oyan AM, Kalland KH, Bjorge T, Akslen LA, et al.: High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer. Br J Cancer 2011, 104(6):921-926.
• [23]Alici S, Kaya S, Izmirli M, Tuncer I, Dogan E, Ozbek H, Sayarlioglu H: Analysis of survival factors in patients with advanced-stage gastric adenocarcinoma. Med Sci Monit 2006, 12(5)):CR221-CR229.
• [24]Parker AS, Lohse CM, Cheville JC, Thiel DD, Leibovich BC, Blute ML: Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma. Urology 2006, 68(4):741-746.
• [25]Abrahamson PE, Gammon MD, Lund MJ, Flagg EW, Porter PL, Stevens J, Swanson CA, Brinton LA, Eley JW, Coates RJ: General and abdominal obesity and survival among young women with breast cancer. Cancer Epidemiol Biomarkers Prev 2006, 15(10):1871-1877.
• [26]Carmichael AR: Obesity and prognosis of breast cancer. Obes Rev 2006, 7(4):333-340.
• [27]Carmichael AR: Obesity as a risk factor for development and poor prognosis of breast cancer. BJOG 2006, 113(10):1160-1166.
• [28]Van Cutsem E, Arends J: The causes and consequences of cancer-associated malnutrition. Eur J Oncol Nurs 2005, 9(Suppl 2):S51-S63.
• [29]Kollarova H, Machova L, Horakova D, Cizek L, Janoutova G, Janout V: Is obesity a preventive factor for lung cancer? Neoplasma 2008, 55(1):71-73.
• [30]Leung CC, Lam TH, Yew WW, Chan WM, Law WS, Tam CM: Lower lung cancer mortality in obesity. Int J Epidemiol 2011, 40(1):174-182.
• [31]Parr CL, Batty GD, Lam TH, Barzi F, Fang X, Ho SC, Jee SH, Ansary-Moghaddam A, Jamrozik K, Ueshima H, et al.: Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: pooled analyses of 424,519 participants. Lancet Oncol 2010, 11(8):741-752.
• [32]Yang R, Cheung MC, Pedroso FE, Byrne MM, Koniaris LG, Zimmers TA: Obesity and weight loss at presentation of lung cancer are associated with opposite effects on survival. J Surg Res 2011, 170(1):e75-e83.
• [33]Lavie CJ, Osman AF, Milani RV, Mehra MR: Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am J Cardiol 2003, 91(7):891-894.
• [34]Kapoor JR, Heidenreich PA: Obesity and survival in patients with heart failure and preserved systolic function: a U-shaped relationship. Am Heart J 2010, 159(1):75-80.
• [35]Gislason T, Nou E: Sedimentation rate, leucocytes, platelet count and haemoglobin in bronchial carcinoma: an epidemiological study. Eur J Respir Dis 1985, 66(2):141-146.
• [36]Pedersen LM, Milman N: Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J 1996, 9(9):1826-1830.
• [37]Qiu MZ, Yuan ZY, Luo HY, Ruan DY, Wang ZQ, Wang FH, Li YH, Xu RH: Impact of pretreatment hematologic profile on survival of colorectal cancer patients. Tumour Biol 2010, 31(4):255-260.
• [38]Qiu MZ, Xu RH, Ruan DY, Li ZH, Luo HY, Teng KY, Wang ZQ, Li YH, Jiang WQ: Incidence of anemia, leukocytosis, and thrombocytosis in patients with solid tumors in China. Tumour Biol 2010, 31(6):633-641.
• [39]Dowlati A, R'Zik S, Fillet G, Beguin Y: Anaemia of lung cancer is due to impaired erythroid marrow response to erythropoietin stimulation as well as relative inadequacy of erythropoietin production. Br J Haematol 1997, 97(2):297-299.
• [40]Caro JJ, Salas M, Ward A, Goss G: Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001, 91(12):2214-2221.
• [41]Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennett C, Engert A: Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005, 97(7):489-498.
• [42]Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, et al.: Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007, 25(9):1027-1032.
• [43]Zarychanski R, Houston DS: Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? CMAJ 2008, 179(4):333-337.
• [44]Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, et al.: High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin Cancer Res 2004, 10(24):8195-8203.
• [45]Kim YT, Kim TY, Lee DS, Park SJ, Park JY, Seo SJ, Choi HS, Kang HJ, Hahn S, Kang CH, et al.: Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung. Lung Cancer 2008, 59(1):111-118.
• [46]Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361(10):947-957.
• [47]Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, et al.: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361(10):958-967.
• [48]Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al.: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(25):2380-2388.